Ombitasvir/dasabuvir with ribavirin therapy led to SVR12 among HCV patients

  • April 24, 2014

Untreated hepatitis C virus genotype 1-infected patients achieved a sustained virologic response 12 weeks after treatment with ombitasvir and dasabuvir, with ribavirin, according to data from a recent study.

Researchers randomized and divided 631 patients into two groups (A, B) in a double-blind, placebo-controlled trial. Group A patients (431) received an oral regimen of ABT-450/r-ombitasvir (a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir and 25 mg of ombitasvir) and 250 mg of dasabuvir (twice daily) with ribavirin. Group B (158) received matching placebos. After the double-blind period, Group B received the active regimen as open-label therapy for 12 weeks. The mean age of group A was 49.4 years and group B was 521.2 years. The primary endpoint was sustained virologic response (SVR) at 12 weeks after treatment.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More »
More »
  • Financial Planning
  • Advice for physicians
  • Be aware of important 2014 IRA updates. Analysis by Certified Financial Planner Ken Rudzinski.
More »
  • Health Care Update
  • Medicare lab payments
  • New law will modernize Medicare lab payments: What physicians need to know. Analysis from Arnold & Porter LLP.
More »
HCV Next